Effectiveness, Safety, and Immunogenicity of a Second COVID‐19 Vaccine Booster in the Elderly: A Systematic Review and Meta‐Analysis Protocol Authors: Marieli Thomazini Piske Garcia, Valeria Valim, Luís Carlos Lopes‐Júnior Published: 2026 ABSTRACT ABSTRACTBackground/AimsOlder adults remain highly vulnerable to severe COVID‐19 outcomes due to immunosenescence and comorbidities. Although booster vaccination strategies have reduced hospitalizations and mortality, evidence regarding the effectiveness, safety, and immunogenicity of a second COVID‐19 vaccine booster dose in older adults remains fragmented. This systematic review and meta‐analysis protocol aims to critically evaluate the available evidence from randomized and nonrandomized clinical trials (NRCTs) regarding the effectiveness, safety, and immunogenicity of the second COVID‐19 vaccine booster in older adults worldwide.MethodsA systematic review of clinical trials will be conducted using PubMed/MEDLINE, EMBASE, Cochrane Library, Web of Science, Scopus, and LILACS, without restrictions on publication date or language. Eligible studies will include randomized controlled trials and NRCTs involving older adults aged ≥ 60 years who received a second COVID‐19 vaccine booster dose. Primary outcomes will include measures related to effectiveness, safety, and/or immunogenicity. Study selection will follow PRISMA‐2020 guidelines. Risk of bias will be assessed using RoB 2 and ROBINS‐I tools, while certainty of evidence will be evaluated using the GRADE approach.ResultsA narrative synthesis will be performed, and meta‐analysis will be conducted whenever methodologically appropriate.ConclusionThis review will provide comprehensive evidence regarding second COVID‐19 booster doses in older adults and may support evidence‐based public health strategies and vaccination policies for high‐risk populations.Trial RegistrationPROSPERO registration number: CRD42025644411. Introduction Coronavirus disease 2019 (COVID‐19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), is a highly transmissible infectious disease primarily affecting the respiratory system [1]. In most cases, infected individuals experience mild to moderate respiratory symptoms [1]. In late 2019, health authorities identified a cluster of pneumonia cases of unknown origin in Wuhan, located in Hubei Province, China. In response to the rapid international spread of the disease, the World Health Organization (WHO) declared COVID‐19 a Public Health Emergency of International Concern on January 30, 2020. As transmission intensified across multiple countries and continents, the WHO officially characterized COVID‐19 as a global pandemic on March 11, 2020 [2]. Globally, from the beginning of the pandemic through December 2025, more than 777 million confirmed cases of COVID‐19 and over 7 million deaths had been reported to the WHO. To mitigate the transmission and impact of SARS‐CoV‐2, the rapid development and large‐scale deployment of COVID‐19 vaccines became a pivotal global public health strategy. By the end of 2025, more than 13.6 billion COVID‐19 vaccine doses had been administered worldwide, with substantial global population coverage achieved through primary vaccination schedules and booster doses [3, 4]. One of the significant challenges of COVID‐19 immunization is the reduced vaccine effectiveness in older adults due to immunological changes associated with aging [5]. Individuals over the age of 70 have demonstrated lower protective efficacy against COVID‐19 compared with the general population, particularly 5 months after receiving the second vaccine dose [6, 7]. A meta‐analysis revealed a progressive increase in mortality rates, from 9.5% in patients aged 60–69 years to 29.6% in those over 80 years of age [8]. Regarding Adverse Events Supposedly Attributable to Vaccination or Immunization (AESAVI), both local and systemic reactions were more prevalent among older adults (OR = 2.57; 95% CI, 1.83–3.62; p < 0.00001). Although mild to moderate adverse events may occur following vaccination in older adults, current evidence consistently demonstrates that COVID‐19 vaccines have a favorable safety profile and are associated with substantial reductions in severe disease, hospitalization, and COVID‐19‐related mortality in this population [9]. Mass immunization against COVID‐19 has played a pivotal role in reducing hospitalization and mortality rates, significantly mitigating the pandemic's impact. This progress has helped alleviate the burden on healthcare systems and facilitated the gradual resumption of social and economic activities on a global scale [10]. Among the priority groups for vaccination, older adults stand out due to their heightened vulnerability to severe complications and fatal outcomes associated with SARS‐CoV‐2 infection. Although many countries have implemented large‐scale vaccination programs with an initial focus on protecting this high‐risk population, the administration of a second booster dose of COVID‐19 has raised important questions regarding its effectiveness, safety, and immunogenicity. Preliminary evidence suggests that this strategy may offer significant benefits in extending immune protection and reducing the incidence of severe disease, particularly in the context of emerging variants [11, 12]. However, the available data remains fragmented, and findings across different regions and populations lack a robust synthesis that provides a comprehensive and evidence‐based perspective. Given the global impact of COVID‐19 and the pressing need for evidence‐based decision‐making to guide public health policies, conducting a rigorous and comprehensive systematic review on the second booster dose in older adults is imperative. The aim of this study is to compile and critically evaluate the available evidence, with a focus on randomized clinical trials (RCTs), to better understand the outcomes related to the effectiveness, safety, and immunogenicity of the second COVID‐19 vaccine booster in older populations worldwide. This review will address existing knowledge gaps and provide a scientific foundation for informed decision‐making regarding public health interventions aimed at protecting older adults, particularly in contexts of high uncertainty and the constantly evolving nature of the pandemic. Methods Study Design and Registration This study protocol was prepared following the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses Protocols (PRISMA‐P) guidelines [13]. The protocol was prospectively registered in the PROSPERO/UK under registration ID: CRD42025644411. Furthermore, the systematic review will adhere closely to the PRISMA Statement 2020 reporting standards [14] to ensure high methodological rigor and transparency. Research Question The research question was structured using the Population, Intervention, Comparison, Outcome, and Study Design (PICOS) framework, which considers the following components: population/patients, intervention, comparison, outcomes, and study design [15]. The elements applied in the present protocol are summarized in Table 1. The PICOS framework guided the formulation of the following research question: “What is the available evidence on the effectiveness, safety, and immunogenicity of the second COVID‐19 vaccine booster dose in older adults worldwide?” Table 1PICOS framework adopted to formulate the research question.AcronymDescription [P] Patient/populationOlder adults aged ≥ 60 years.a [I] InterventionSecond COVID‐19 vaccine booster dose, administered after the completion of the primary vaccination schedule and the first booster dose. [C] Control or comparisonOlder adults who received only the first booster dose or no additional booster beyond the primary vaccination schedule. [O] Outcomesb Effectiveness: Reduction in COVID‐19 cases, hospitalizations, and mortality.Safety: Frequency and severity of adverse events associated with the second booster dose.Immunogenicity: Antibody levels and immune responses postvaccination. [S] Study designRandomized clinical trials (RCTs) and nonrandomized clinical trials (NRCTs) a World Health Organization, 2025 [16]. b Studies reporting at least one of the predefined primary outcomes will be considered eligible for inclusion in the review.John Wiley & Sons, Ltd. PICOS framework adopted to formulate the research question. Effectiveness: Reduction in COVID‐19 cases, hospitalizations, and mortality.Safety: Frequency and severity of adverse events associated with the second booster dose.Immunogenicity: Antibody levels and immune responses postvaccination. Effectiveness: Reduction in COVID‐19 cases, hospitalizations, and mortality. Effectiveness: Reduction in COVID‐19 cases, hospitalizations, and mortality. Safety: Frequency and severity of adverse events associated with the second booster dose. Safety: Frequency and severity of adverse events associated with the second booster dose. Immunogenicity: Antibody levels and immune responses postvaccination. Immunogenicity: Antibody levels and immune responses postvaccination. World Health Organization, 2025 [16]. Studies reporting at least one of the predefined primary outcomes will be considered eligible for inclusion in the review. Search Strategy The literature search will be performed in six electronic databases: EMBASE, MEDLINE/PubMed, Cochrane Library, Web of Science, Scopus, and LILACS. Studies published from database inception through December 31, 2025, will be considered eligible for screening. Search strategies will be customized for each database using controlled vocabulary terms (e.g., MeSH and Emtree), related synonyms, and relevant free‐text terms. The descriptors will be combined using Boolean operators (“AND,” “OR,” and “NOT”) to improve search sensitivity and specificity [17, 18, 19, 20, 21]. No restrictions regarding language, publication period, or study setting will be imposed. To enhance the comprehensiveness of the review, additional searches will be conducted in ClinicalTrials.gov and the WHO/ICTRP. Furthermore, the reference lists of all included studies will be manually examined to identify potentially eligible publications not retrieved during the primary database search. All retrieved records will be imported into EndNote software for organization, storage, and duplicate management. The search process will be designed and conducted by a researcher with expertise in systematic reviews and evidence synthesis (LCLJ). Initially, relevant indexing terms and keywords specific to each database will be identified, followed by the development of search combinations using Boolean operators to maximize retrieval of relevant studies. Moreover, the search will employ descriptors with expanded meanings but without database‐specific filters, preserving significant samples and minimizing the risk of missing relevant studies. The search strategy developed for MEDLINE/PubMed, incorporating both MeSH terms and free‐text keywords, will be adapted for other databases as depicted in Table 2. Table 2Search strategy developed for the MEDLINE/PubMed database.Search strategyMEDLINE/PubMedItems searched#1: (“Aged” [MeSH Terms] OR “Elderly” [Title/Abstract] OR “Middle Aged” [MeSH Terms] OR “Middle Age” [Title/Abstract] OR “Aged, 80 and over” [MeSH Terms] OR “Oldest Old” [Title/Abstract])#2: (“COVID‐19 Vaccines” [MeSH Terms] OR “COVID 19 Vaccines” [Title/Abstract] OR “Vaccines, COVID‐19” [Title/Abstract] OR “Virus Vaccines, COVID‐19” [Title/Abstract] OR “COVID‐19 Virus Vaccine” [Title/Abstract] OR “COVID 19 Virus Vaccine” [Title/Abstract] OR “COVID19 Vaccines” [Title/Abstract] OR “COVID19 Vaccine” [Title/Abstract] OR “SARS‐CoV‐2 Vaccines” [Title/Abstract] OR “SARS CoV 2 Vaccines” [Title/Abstract] OR “Vaccines, SARS‐CoV‐2” [Title/Abstract] OR “SARS‐CoV‐2 Vaccine” [Title/Abstract] OR “SARS CoV 2 Vaccine” [Title/Abstract] OR “Vaccine, SARS‐CoV‐2” [Title/Abstract] OR “SARS2 Vaccines” [Title/Abstract] OR “Coronavirus Disease 2019 Vaccines” [Title/Abstract] OR “Coronavirus Disease 2019 Vaccine” [Title/Abstract] OR “Coronavirus Disease‐19 Vaccines” [Title/Abstract] OR “Coronavirus Disease 19 Vaccines” [Title/Abstract] OR “Coronavirus Disease‐19 Vaccine” [Title/Abstract] OR “Coronavirus Disease 19 Vaccine” [Title/Abstract] OR “COVID 19 Vaccine” [Title/Abstract] OR “Vaccine, COVID 19” [Title/Abstract] OR “2019‐nCoV Vaccine” [Title/Abstract] OR “2019 nCoV Vaccine” [Title/Abstract] OR “2019 Novel Coronavirus Vaccine” [Title/Abstract] OR “2019‐nCoV Vaccines” [Title/Abstract] OR “COVID‐19 Vaccine” [Title/Abstract] OR “Vaccine, COVID‐19” [Title/Abstract] OR “SARS Coronavirus 2 Vaccines” [Title/Abstract])#3: #1 AND #2#4: (“Vaccine Efficacy” [MeSH Terms] OR “Efficacy, Vaccine” [Title/Abstract] OR “Vaccine Effectiveness” [Title/Abstract] OR “Immunogenicity, Vaccine” [MeSH Terms] OR “Vaccine Immunogenicity” [Title/Abstract] OR “Antigenicity, Vaccine” [Title/Abstract] OR “Vaccine Antigenicity” [Title/Abstract] OR “Pharmacovigilance” [MeSH Terms] OR “Pharmacovigilances” [Title/Abstract] OR “Adverse effects” [MeSH Terms] OR “Side effects” [Title/Abstract])#5: #3 AND #4#6: “randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized [tiab] OR placebo [tiab] OR clinical trials as topic [MeSH Terms:noexp] OR randomly [tiab])”#7: #5 AND #6John Wiley & Sons, Ltd. Search strategy developed for the MEDLINE/PubMed database. Eligibility Inclusion Criteria Studies describing the effectiveness, safety, and immunogenicity of the second booster dose of the COVID‐19 vaccine in older adults aged ≥ 60 years across various countries worldwide will be conducted. Additionally, studies reporting at least one of the primary outcomes of interest—effectiveness, safety, and/or immunogenicity of the second COVID‐19 vaccine booster dose in older adults aged ≥ 60 years—will be considered eligible for inclusion. Both randomized controlled trials and nonrandomized clinical trials (NRCTs) (quasi‐experimental studies) using intention‐to‐treat and/or per‐protocol analyses will be considered eligible, provided that sufficient outcome data are reported. Exclusion Criteria Studies with observational, qualitative, review‐based, or gray literature designs will not be considered eligible for inclusion in this review. The study selection process will not impose restrictions related to language or year of publication. Selection Studies will be independently and blindly reviewed by two researchers. Following this initial selection, a third reviewer will evaluate and decide on the inclusion or exclusion of articles, particularly those with conflicting information. To support the screening and eligibility assessment process, the Rayyan platform developed by the Qatar Computing Research Institute will be used to manage study inclusion and exclusion decisions [22]. Data Extraction Two researchers (MTP and LCLJ) will independently extract data using pre‐established and adapted tools [17, 18, 19, 20, 21, 23, 24]. The extracted information will include: 1. General Study Information: Title of the article, year of publication, country where the study was conducted, study setting, sources of funding, and declarations of conflicts of interest.2. Methodological Features: Information related to study design, trial registration, study location, research objectives, participant eligibility criteria, sample size, baseline characteristics of intervention and comparison groups, recruitment procedures, allocation methods, blinding procedures, intervention characteristics, follow‐up duration, participant losses, outcome measures, and statistical methods used.3. Key Findings and Clinical Relevance: Main study outcomes and their potential implications for clinical practice and public health decision‐making.4. Limitations: Limitations of the study.5. Conclusions: Final key message and conclusions. 1. General Study Information: Title of the article, year of publication, country where the study was conducted, study setting, sources of funding, and declarations of conflicts of interest. General Study Information: Title of the article, year of publication, country where the study was conducted, study setting, sources of funding, and declarations of conflicts of interest. 2. Methodological Features: Information related to study design, trial registration, study location, research objectives, participant eligibility criteria, sample size, baseline characteristics of intervention and comparison groups, recruitment procedures, allocation methods, blinding procedures, intervention characteristics, follow‐up duration, participant losses, outcome measures, and statistical methods used. Methodological Features: Information related to study design, trial registration, study location, research objectives, participant eligibility criteria, sample size, baseline characteristics of intervention and comparison groups, recruitment procedures, allocation methods, blinding procedures, intervention characteristics, follow‐up duration, participant losses, outcome measures, and statistical methods used. 3. Key Findings and Clinical Relevance: Main study outcomes and their potential implications for clinical practice and public health decision‐making. Key Findings and Clinical Relevance: Main study outcomes and their potential implications for clinical practice and public health decision‐making. 4. Limitations: Limitations of the study. Limitations: Limitations of the study. 5. Conclusions: Final key message and conclusions. Conclusions: Final key message and conclusions. Data extraction will be independently performed by the reviewers using standardized Microsoft Excel spreadsheets specifically developed for this review. After completion of the extraction process, all collected information will be reviewed, compared, and merged into a unified database for subsequent analysis. Addressing Missing Data When relevant information is unavailable, incomplete, or unclear in the included studies, the reviewers (MTP and LCLJ) will attempt to obtain additional details by contacting the corresponding authors via email. Supporting materials and related documents associated with the publications will also be examined to retrieve missing information whenever possible. Studies for which essential data cannot be obtained will be described narratively and considered during the interpretation of findings, although they may be excluded from quantitative synthesis when appropriate. Methodological Appraisal The methodological quality and potential risk of bias of the included RCTs will be evaluated using the revised Cochrane Risk‐of‐Bias tool for randomized trials (RoB 2) [25]. This instrument examines five major domains related to bias: the randomization process, deviations from intended interventions, incomplete outcome data, outcome assessment, and selective reporting. On the basis of these domains, studies will be categorized as presenting low risk of bias, some concerns, or high risk of bias [25]. For NRCTs, the Risk Of Bias In Nonrandomized Studies of Interventions (ROBINS‐I) tool will be applied [26]. This instrument assesses potential sources of bias occurring before, during, and after the intervention, allowing studies to be classified according to the severity of bias as low, moderate, serious, or critical [26]. Risk‐of‐bias assessments will be independently conducted by two reviewers. Any disagreements identified during the appraisal process will be resolved through discussion and consensus between the reviewers. Results and Evidence Synthesis Presentation A descriptive and narrative synthesis of the included studies will be performed, considering: 1. Study Quality Characteristics: Information on the number of dropouts during follow‐up, early withdrawal due to benefit, intention‐to‐treat analysis, blinding methods, allocation concealment, and randomization procedures.2. Vaccine Protocol Characteristics: Details about the intervention and control groups, including sample size, treatment duration, dose, and vaccine administration intervals.3. Population Characteristics: Information on age range, disease staging, co‐treatment or surgeries, and other relevant demographic and clinical data.4. Outcomes: Changes in immunological parameters, effectiveness measures, and safety data. 1. Study Quality Characteristics: Information on the number of dropouts during follow‐up, early withdrawal due to benefit, intention‐to‐treat analysis, blinding methods, allocation concealment, and randomization procedures. Study Quality Characteristics: Information on the number of dropouts during follow‐up, early withdrawal due to benefit, intention‐to‐treat analysis, blinding methods, allocation concealment, and randomization procedures. 2. Vaccine Protocol Characteristics: Details about the intervention and control groups, including sample size, treatment duration, dose, and vaccine administration intervals. Vaccine Protocol Characteristics: Details about the intervention and control groups, including sample size, treatment duration, dose, and vaccine administration intervals. 3. Population Characteristics: Information on age range, disease staging, co‐treatment or surgeries, and other relevant demographic and clinical data. Population Characteristics: Information on age range, disease staging, co‐treatment or surgeries, and other relevant demographic and clinical data. 4. Outcomes: Changes in immunological parameters, effectiveness measures, and safety data. Outcomes: Changes in immunological parameters, effectiveness measures, and safety data. Whenever appropriate and methodologically feasible, continuous and dichotomous outcomes will be aggregated for meta‐analysis to quantify pooled effects and enhance the interpretation of findings. The final selection of studies will be summarized using a PRISMA flow diagram (Figure 1). PRISMA‐2020 flow diagram template illustrating the planned study selection process for this review. The final flowchart, including the numbers of identified, screened, excluded, and included studies and the reasons for exclusion, will be completed during the conduct of the review. Data Analysis Heterogeneity among studies will be assessed using the I 2 statistic, which estimates the percentage of variation across studies due to heterogeneity. The following thresholds will be used to interpret I 2 values: ▪ I 2 = 0%–20%: Low heterogeneity.▪ I 2 = 25%–50%: Moderate heterogeneity.▪ I 2 = 51%–75%: Substantial heterogeneity.▪ I 2 = > 75%: High heterogeneity [27]. ▪ I 2 = 0%–20%: Low heterogeneity. I 2 = 0%–20%: Low heterogeneity. ▪ I 2 = 25%–50%: Moderate heterogeneity. I 2 = 25%–50%: Moderate heterogeneity. ▪ I 2 = 51%–75%: Substantial heterogeneity. I 2 = 51%–75%: Substantial heterogeneity. ▪ I 2 = > 75%: High heterogeneity [27]. I 2 = > 75%: High heterogeneity [27]. Meta‐analysis will be conducted when the included studies are considered sufficiently homogeneous regarding population characteristics, interventions, comparators, study designs, and reported outcomes, and when adequate quantitative data are available for pooling. Statistical heterogeneity among studies will be assessed using the I 2 statistic, which will inform the interpretation of pooled estimates and the choice between fixed‐effect and random‐effects models [27]. If appropriate, the statistical model used for estimating pooled effects will be selected as either a fixed‐effects model or a random‐effects model. For data analysis, pooled effect estimates will include a 95% confidence interval (CI) with a significance level of α = 0.05, using the EPPI‐Reviewer software (United Kingdom). Effect estimates from the included studies will be converted to a standardized metric to facilitate comparisons across different study designs and outcome measures. For continuous outcomes, pooled estimates will be calculated using the bias‐adjusted standardized mean difference (Hedges' g) [28]. In the interpretation of results, positive values will indicate greater benefit in the intervention group, whereas negative values will favor the comparison group [23, 25, 27]. The certainty and overall quality of the evidence will be evaluated according to Cochrane recommendations and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework [29]. Evidence quality will be categorized into four levels: high, moderate, low, or very low certainty. Two reviewers (LCLJ and MTPG) will independently perform the critical appraisal and evidence assessment procedures. In cases of disagreement, a third reviewer (VV) will be consulted to achieve consensus. Potential publication bias will be investigated through visual inspection of funnel plots and application of the Duval and Tweedie trim‐and‐fill method [30]. These analyses will only be performed when an adequate number of studies are available for a given outcome [28, 30]. Patient and Public Involvement and Ethics and Dissemination Patients will not be directly involved in the design of this study. As this study is a systematic review and meta‐analysis protocol based exclusively on previously published and publicly available data, ethical approval and informed consent are not required. No individual patient data will be collected, and no participants will be directly involved in the conduct of this study. The review will be conducted in accordance with the PRISMA‐2020 [14] and PRISMA‐P guidelines [13]. Any modifications made to this protocol throughout the review process will be clearly documented and reported. Detailed records of search strategies, database queries, screening procedures, and analytical decisions will be maintained using bibliographic management software and standardized data extraction files to ensure transparency and reproducibility. The results of the completed systematic review and meta‐analysis will be disseminated through publication in peer‐reviewed scientific journals and presentation at national and international scientific meetings. Discussion Older adults remain disproportionately vulnerable to severe COVID‐19 outcomes due to immunosenescence, multimorbidity, frailty, and waning vaccine‐induced immunity over time [9, 11, 12]. Although primary vaccination schedules substantially reduced COVID‐19‐related hospitalizations and mortality worldwide, emerging SARS‐CoV‐2 variants and the progressive decline in immune protection have reinforced the importance of additional booster strategies, particularly among high‐risk populations [31, 32, 33]. Several countries implemented second COVID‐19 booster dose strategies for older adults following evidence suggesting improved protection against severe disease, hospitalization, and death during periods dominated by Omicron and its subvariants [34, 35, 36, 37, 38]. Recent studies evaluating fourth‐dose vaccination strategies in older populations demonstrated favorable effectiveness and immunogenicity profiles, including enhanced neutralizing antibody responses and reduced rates of severe COVID‐19 outcomes [11, 12]. A cumulative meta‐analysis revealed that COVID‐19 vaccines effectively prevent severe SARS‐CoV‐2 infections (OR = 0.38; 95% CI, 0.23–0.65; p = 0.0004) and reduce mortality (OR = 0.16; 95% CI, 0.20–0.25; p < 0.00001) in older adults. Additionally, a significant increase in seroconversion rates and geometric mean titers (GMTs) was observed among vaccinated elderly individuals (OR = 24.42; 95% CI, 19.29–30.92; standardized mean difference = 0.92; 95% CI, 0.64–1.20) [9]. In addition, booster doses maintain an acceptable safety profile among older adults, with most reported adverse events being mild to moderate and self‐limited [9]. Despite these advances, the currently available evidence remains heterogeneous regarding study design, vaccine platforms, follow‐up periods, evaluated outcomes, and populations investigated. Furthermore, evidence specifically focused on second booster doses in older adults remains fragmented across different countries and healthcare settings. Therefore, conducting a systematic review and meta‐analysis is essential to comprehensively synthesize the current evidence regarding the effectiveness, safety, and immunogenicity of second COVID‐19 vaccine booster doses in older adults worldwide. This systematic review and meta‐analysis protocol was developed to ensure methodological transparency, reproducibility, and rigor in the identification, selection, appraisal, and synthesis of the available evidence. The findings of the future review may contribute to evidence‐based vaccination policies and public health strategies aimed at protecting older adults against severe COVID‐19 outcomes. Conclusion This systematic review and meta‐analysis protocol was developed to address important gaps in the current evidence regarding the effectiveness, safety, and immunogenicity of second COVID‐19 vaccine booster doses in older adults. Given the ongoing circulation of SARS‐CoV‐2 variants, the progressive waning of vaccine‐induced immunity, and the increased vulnerability of older populations to severe COVID‐19 outcomes, a comprehensive synthesis of the available evidence is essential to support evidence‐based public health decision‐making and vaccination strategies worldwide. The planned review may contribute to a better understanding of the benefits and potential limitations of second booster dose strategies in older adults, while also identifying methodological inconsistencies, research gaps, and priorities for future investigations. Furthermore, the findings may support the development of more robust clinical studies and strengthen vaccination policies aimed at reducing severe disease, hospitalization, and mortality among high‐risk populations. Potential limitations of the future review may include the methodological quality of the primary studies and the expected clinical, methodological, and statistical heterogeneity among included investigations. Variations in vaccine platforms, study designs, follow‐up periods, circulating SARS‐CoV‐2 variants, participant characteristics, comorbidity profiles, and outcome measurement methods may contribute to heterogeneity across studies and should be carefully considered during evidence synthesis and interpretation. Author Contributions Marieli Thomazini Piske Garcia: conceptualization, investigation, writing – original draft, writing – review and editing, data curation. Valeria Valim: conceptualization, validation, visualization, writing – review and editing, data curation, project administration. Luís Carlos Lopes‐Júnior: conceptualization, methodology, software, data curation, investigation, validation, formal analysis, supervision, funding acquisition, visualization, project administration, resources, writing – original draft; writing – review and editing. Funding The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Transparency Statement Prof. Dr. Luís Carlos Lopes‐Júnior, corresponding author and manuscript guarantor, confirms that this manuscript provides a truthful, clear, and complete description of the study protocol. The author further declares that no relevant aspects of the study were intentionally omitted and that any modifications to the original protocol or registered methods have been properly described and justified. Supporting information Supporting File